A B S T R A C T The hypophosphatemic male mouse, an animal model for human vitamin D-resistant rickets, is characterized by low serum phosphorus concentration due to increased urinary phosphate excretion, rickets, osteomalacia, and dwarfism. Because phosphate administration can heal rickets but not osteomalacia in the human disease, we have compared the effect of phosphate supplementation on the epiphyseal and endosteal bone mineralization in the mutant animal. Phosphate was given in drinking water for 137 
INTRODUCTION
The hypophosphatemic (Hyp)l mouse has been proposed as a valuable animal model for human vitamin D-resistant rickets (VDRR) (1) . As in the human disease, the mutation is transmitted as an X-linked dominant trait and causes hypophosphatemia due to an intrinsic renal tubular reabsorption defect for phosphate (2) . Moreover, the Hyp mouse has a mild hypocalcemia (1) and reduced bone magnesium (Mg) content (3) . Besides these biochemical abnormalities, the mutant animal presents with growth retardation resulting from rickets (1) and skeletal deformities associated with histologic evidence of osteomalacia (3) . In children with VDRR, the radiological appearance of rickets can be healed by adequate supplementation of phosphate (Pi) (4) whereas osteomalacia remains uncured (5, 6 ). The present study was designed to evaluate the effect of Pi on the epiphyseal and endosteal mineralization in the affected male mouse.
METHODS
Animals. At weaning, six normal male mice (+/Y) and seven hemizygous mutants (Hyp/Y) from the C57BL/6J strain were fed a mouse Purina chow containing 0.50% calcium and 0.74% phosphorus. Pi (Table I) .
Bone growth failure and defective epiphyseal calcification were demonstrated in untreated Hyp/Y mice by a shorter than normal vertebral length associated with a wide epiphyseal growthplate (Table II, Fig. 1A and B) . Impaired endosteal bone mineralization was evidenced by excessive osteoid surface (87.0±3.1 vs. +/Y 3.8±1.5%, P < 0.001) and thickness, and decreased extent of the mineralization front (Table II) . After treatment with Pi, the vertebral length was increased but remained shorter than normal, while the growthplate thickness was reduced within the normal range and metaphyseal calcification of the primary spongiosa was induced (Table   TABLE II (0) remain excessively large along the calcified bone matrix (BM). Undecalcified, toluidine blue stained section, x 100.
II, Fig. 1B and C) . At the diaphyseal level, the osteoid surface was unchanged (82.0±2.9%), the mineralization front was poorly improved while the periosteal but not the endosteal osteoid thickness was slightly reduced but not normalized. On the other hand, the extent of active osteoblasts and both the osteoclastic surface and the number of osteoclasts were markedly increased along the endosteal bone surface (Table II) .
DISCUSSION
The present study demonstrates that, as in human VDRR (4, 6, 10) , the rachitic lesion can be healed by Pi in the hypophosphatemic mouse. Although serum phosphorus measured in the fasting state was unchanged during Pi therapy, the marked elevation of Pi excretion shows that treated mice had a higher Pi absorption. The increased Mg excretion associated in untreated Hyp/Y with a slight hypermagnesemia appears to result from the deranged Pi homeostasis since correction of serum and urinary Mg concentrations could be achieved by Pi supplementation. In the rat, Pi depletion increases the Mg intestinal absorption and decreases the net renal tubular reabsorption of Mg with the main source of urinary loss being bone (11) . In Hyp/Y mice, it is possible that correction ofbone Mg content will require the normalization of endosteal bone mineralization.
As evidenced by correction of the growthplate thickness by Pi, normalization of the epiphyseal and metaphyseal calcification was achieved despite a Pi-induced drop in serum calcium. Although both calcium and Pi are essential for optimal epiphyseal mineralization, Pi seems to be the critical mineral required in the process (10, (12) (13) (14) . As in VDRR (5), correction of epiphyseal calcification by Pi was associated with increased overall body length (1). The mutant animals, however, did not catch up within the normal range. This may be due to the severity of the bone disease already present at the onset of treatment.
As in the human disease, improvement of bone growth was associated with reduction of serum alkaline phosphatase concentration (5, 6) . However, serum alkaline phosphatase was not corrected, which probably reflects the persistent abnormality of the endosteal bone mineralization. This discrete response of the epiphyseal and endosteal bone to Pi is fully in accordance with our findings in the human disease (5, 6 ).
This may be due to the different ways minerals are supplied to the two regions and/or to a greater sensitivity of the epiphyseal cells to extracellular Pi concentration as compared with the endosteal cells (6) .
In line with the human disease (5, 6) and with experimental studies in the rat (15) (5, 6) , bone turnover was greatly stimulated as a result of the probable increase in PTH secretion (15) .
Our results show that the effects of Pi supplementation on the epiphyseal and endosteal bone mineralization and turnover are similar in Hyp/Y mice and VDRR children. In the latter, recent data showed that improvement of endosteal bone mineralization and prevention of Pi-induced secondary hyperparathyroidism require the pharmacologic use of 1,25-dihydroxyvitamin D3 combined with Pi supplementation (6) . A similar therapeutic approach, in the mutant animal, is currently under way in our laboratory.
